
When Novo Nordisk announced in December that it would commence studies with oral semaglutide for treating Alzheimer's, the firm expected that this would happen in the course of the first half-year of 2021.
According to database clinicaltrials.gov, Novo Nordisk is now one step closer to starting this process. The firm has registered two studies for the disease, which are currently scheduled to start on May 18.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Fruergaard leveraging experience from Danish partnerships in key roles in Brussels
Experiences from Danish climate partnerships are among the tools that can be leveraged when Novo Nordisk CEO Lars Fruergaard begins stepping up efforts in the life science sector’s central organs in Brussels. ”I’ve been fired up by the intimacy and shared vision we could see in Denmark,” he tells MedWatch.